ARUP's Laboratory Test Directory
| 0095864: Paroxysmal Nocturnal Hemoglobinuria Profile, High Resolution - RBC |
| Test Mnemonic: PNH | |
|
Methodology: Flow Cytometry
Performed: Sun-Sat Reported: 1-4 days |
| Specimen Required: | |
|
Collect: One 5 mL green (sodium or lithium heparin), lavender (EDTA), or pink (K2EDTA).
Transport: 5 mL whole blood at 2-8°C. Pediatric Collection/Transport: 0.5 mL whole blood at 2-8°C. Stability: Ambient: 4 days; Refrigerated: 4 days; Frozen: Unacceptable |
|
| Reference Interval: | |||||||||
|
| Interpretive Data: | |
|
The High Resolution PNH-RBC panel detects the absence of phosphatidylinositol-linked membrane proteins CD55 (DAF-decay accelerating factor) and CD59 (MIRL-membrane inhibitor of reactive lysis) on erythrocytes. The erythrocytes are identified with glycophorin staining. All normal RBCs (99.995-100.000%) express CD55 and CD59 and are reported as % Normal RBCs. The expression of CD55 and CD59 is decreased or absent in a subpopulation of RBCs in patients with paroxysmal nocturnal hemoglobinuria. The estimated percentage of RBCs with decreased expression is reported as % PNH cells. The detection of a very low percentile of PNH cells (0.006-1.000%) may be found in patients with aplastic anemia, myelodysplasia, refractory anemia, refractory anemia with excess blasts, and myelofibrosis. The presence of PNH cells in these patients may correlate with a better prognosis. Blood 102:1211-1218 (2003) Please refer to Statement A in the Compliance Statements section in the front of the Laboratory Test Directory. |
| Note: | |
| This panel tests for the phosphatidylinositol-linked membrane proteins CD55 (DAF-decay accelerating factor) and CD59 (MIRL-membrane inhibitor of reactive lysis) on erythrocytes. The percentage of RBCs with normal expression of CD55 and CD59 is decreased in paroxysmal nocturnal hemoglobinuria (PNH). |
| CPT Code(s): | |
| 88184 First marker; 88185 x2 Each additional marker |